Objective To observe the clinical efficacy of Na Zhi method (midnight-noon ebb-flow method) plus electroacupuncture in treating poststroke uninhibited neurogenic bladder.Method A total of 120 patients with uninhibited neurogenic bladder due to cerebrovascular diseases were randomized into a treatment group and a control group, 60 cases in each group. The treatment group was intervened by Na Zhi method plus electroacupuncture; the control group was intervened by electroacupuncture. The intervention was conducted once a day, 30 min each time, for a total of 2 weeks. The daily voiding frequency index and maximum cystometric capacity (MCC) in the two groups were measured before and after the intervention, and the clinical efficacies were compared.Result The total effective rate and markedly effective rate were respectively 98.2% and 89.5% in the treatment group versus 93.1% and 72.4% in the control group. There was a significant difference in comparing the markedly effective rate between the two groups (P<0.05). There was no significant difference in comparing the daily voiding frequency index between the two groups before the intervention (P>0.05); the daily voiding frequency index was significantly changed after the intervention in both groups (P<0.01), and the daily voiding frequency index of the treatment group was significantly different from that of the control group after the intervention (P<0.05). There was no significant difference in comparing the MCC before the intervention between the two groups (P>0.05); the MCC was significantly changed after the intervention in both groups (P<0.01); the MCC of the treatment group was significantly different from that of the control group after the intervention (P<0.05).Conclusion Electroacupuncture can produce a significant efficacy in treating uninhibitedneurogenic bladder, while it can produce a more significant efficacy when combined withNa Zhi method.

Objective: To investigate the efficacy and safety of Liqingtong (LQT) granules in patients with dampness-heat hyperuricemia. Methods: A randomized, double-blind, placebo-controlled pilot trial was conducted at the 983rd Hospital of the Joint Logistic Support Force of the People's Liberation Army from March 15, 2023, to August 10, 2023. In total, 119 participants were enrolled in this trial, and participants were given either LQT granules or placebo for 60 days based on a health education. The primary outcome was serum uric acid (SUA) level, and the secondary outcome was the traditional Chinese medicine (TCM) symptom score, measured on days 0, 30, and 60. Safety indicators, including liver function, kidney function, blood routine, glucose, blood lipid, blood pressure, and heart rate were tested on days 0 and 60 of the trial. The data were analyzed using Prism 9 software, and the significance level was set at P < .05. Results: Among 119 participants, six in the LQT granule group and seven in the placebo group dropped out, and 106 participants completed clinical observation. Baseline information, including SUA levels, TCM symptom scores, and other clinical characteristics, did not differ between the groups. At the end of the trial, compared with baseline values, the SUA levels in the LQT granule group decreased (P < .001), and no significant change was observed in the placebo group (P = .422); compared with the placebo group, the SUA levels decreased in the LQT granule group (P = .001). Compared with baseline values, the total TCM symptom scores in the LQT granule group decreased (P < .001), with no change in the placebo group (P = .136). Safety indicators did not differ significantly between the two groups. Conclusion The pilot trial demonstrated the potential of LQT granules to lower SUA levels and improve symptoms of dampness and heat.